We are live on ! Find out more
IMVT icon

Immunovant
IMVT

115 hedge funds and large institutions have $1.37B invested in Immunovant in 2020 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 53 increasing their positions, 20 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

255% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 11

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

165% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 20

96% more capital invested

Capital invested by funds: $696M → $1.37B (+$670M)

32% more funds holding

Funds holding: 87 → 115 (+28)

2% more ownership

Funds ownership: 43.23% → 45.23% (+2%)

Holders
115
Holders Change
+28
Holders Change %
+32.18%
% of All Funds
2.32%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.12%
New
39
Increased
53
Reduced
20
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RI
RTW Investments
New York
+$53.9M
2
CAM
Cormorant Asset Management
Massachusetts
+$49.3M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$44.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$41M
5
BlackRock
BlackRock
New York
+$36.9M

Top Sellers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$31.9M
2
LGM
Logos Global Management
California
-$15.2M
3
RG
Redmile Group
California
-$14.4M
4
CCM
Camber Capital Management
Massachusetts
-$10.9M
5
O
OrbiMed
New York
-$8.63M
Name Holding Trade Value Shares
Change 		Change in
Stake
EVM
26
Eaton Vance Management
Massachusetts
$9.64M +$8.24M +274,069 New
ACP
27
Acuta Capital Partners
California
$8.8M -$3.01M -100,000 -29%
Charles Schwab
28
Charles Schwab
California
$8.75M +$2.79M +92,890 +60%
Invesco
29
Invesco
Georgia
$8.61M +$2.85M +94,776 +63%
MP
30
Mangrove Partners
Connecticut
$8.11M +$3.01M +100,000 +77%
CS
31
Candriam SCA
Luxembourg
$7.74M +$2.41M +80,000 +57%
T. Rowe Price Associates
32
T. Rowe Price Associates
Maryland
$7.23M +$6.18M +205,550 New
Fidelity Investments
33
Fidelity Investments
Massachusetts
$7.04M +$6.02M +200,000 New
PCM
34
Pinz Capital Management
New York
$7.01M +$5.99M +199,100 New
PCM
35
Peregrine Capital Management
Minnesota
$6.32M +$5.4M +179,665 New
AllianceBernstein
36
AllianceBernstein
Tennessee
$6.17M +$2.01M +66,756 +61%
SFM
37
Sphera Funds Management
Israel
$5.98M +$1.95M +65,000 +62%
PVI
38
Pura Vida Investments
New York
$5.6M -$3.36M -111,780 -41%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$5.43M +$2.39M +79,342 +106%
PHP
40
Parkman Healthcare Partners
Connecticut
$5.28M +$753K +25,026 +20%
WP
41
Woodline Partners
California
$4.97M -$2.7M -89,738 -39%
Goldman Sachs
42
Goldman Sachs
New York
$4.34M -$819K -27,236 -18%
PI
43
Putnam Investments
Massachusetts
$4.29M +$318K +10,569 +10%
RG
44
Redmile Group
California
$4.26M -$14.4M -479,060 -80%
ACM
45
Atika Capital Management
New York
$4.12M +$3.52M +117,000 New
California Public Employees Retirement System
46
California Public Employees Retirement System
California
$2.82M +$1.14M +37,857 +89%
Swiss National Bank
47
Swiss National Bank
Switzerland
$2.61M +$680K +22,600 +44%
Wells Fargo
48
Wells Fargo
California
$2.25M +$631K +20,967 +49%
Aviva
49
Aviva
United Kingdom
$2.24M -$781K -25,968 -29%
Two Sigma Investments
50
Two Sigma Investments
New York
$2.12M +$1.54M +51,198 +560%
1
2
3 4 5

IMVT Hedge Fund Activity: Q3 2020 in Review

115 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2020, worth a combined $1.37B — up 96% from $696M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new IMVT positions and 11 closed out — a net gain of 28 holders — while 53 added to existing stakes and 20 trimmed.

The largest buyer was RTW Investments, adding an estimated $53.9M. The largest seller was Adage Capital Partners, cutting an estimated $31.9M.

  • 115 institutional investors held Immunovant (IMVT) as of Q3 2020, up from 87 in Q2 2020.
  • Funds reported $1.37B of Immunovant stock for Q3 2020, up 96% quarter-over-quarter.
  • 39 funds opened new Immunovant positions in Q3 2020 and 11 closed out, a net change of +28 holders.
  • The largest Immunovant buyer in Q3 2020 was RTW Investments, an estimated $53.9M added.
  • The largest Immunovant seller in Q3 2020 was Adage Capital Partners, an estimated $31.9M sold.

Based on aggregated 13F filings for Q3 2020.